Prognosis of microwave ablation for hepatocellular carcinoma: does age make a difference?

References

• International Agency for Research on Cancer, WHO. Estimated number of deaths in 2018, all cancers, both sexes, ages 70+. 2018 [cited 2019 Jun 24]. Available from: http://gco.iarc.fr/today/
   Google Scholar
• Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391:1301–1314.
   PubMed Web of Science ®Google Scholar
• Seki T, Wakabayashi M, Nakagawa T, et al. Ultrasonically guided percutaneous microwave coagulation therapy for small hepatocellular carcinoma. Cancer. 1994;74:817–825.
   PubMed Web of Science ®Google Scholar
• Dong BW, Liang P, Yu XL, et al. Sonographically guided microwave coagulation treatment of liver cancer: an experimental and clinical study. AJR Am J Roentgenol. 1998;171:449–454.
   PubMed Web of Science ®Google Scholar
• Liang P, Wang Y, Yu X, et al. Malignant liver tumors: treatment with percutaneous microwave ablation–complications among cohort of 1136 patients. Radiology. 2009;251:933–940.
   PubMed Web of Science ®Google Scholar
• Chu KF, Dupuy DE. Thermal ablation of tumours: biological mechanisms and advances in therapy. Nat Rev Cancer. 2014;14:199–208.
   PubMed Web of Science ®Google Scholar
• Liang P, Dong B, Yu X, et al. Prognostic factors for survival in patients with hepatocellular carcinoma after percutaneous microwave ablation. Radiology. 2005;235:299–307.
   PubMed Web of Science ®Google Scholar
• Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35:421–430.
   PubMed Web of Science ®Google Scholar
• Omata M, Cheng A-L, Kokudo N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11:317–370.
   PubMed Web of Science ®Google Scholar
• Yao XI, et al. Reporting and guidelines in propensity score analysis: a systematic review of cancer and cancer surgical studies. J Natl Cancer Inst. 2017;109:djw323.
   PubMedGoogle Scholar
• von Elm E, Altman DG, Egger M, et al.; STROBE Initiative. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370:1453–1457.
   PubMed Web of Science ®Google Scholar
• Dong B, Liang P, Yu X, et al. Percutaneous sonographically guided microwave coagulation therapy for hepatocellular carcinoma: results in 234 patients. AJR Am J Roentgenol. 2003;180:1547–1555.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–383.
   PubMedGoogle Scholar
• Quan H, Li B, Couris CM, et al. Updating and validating the charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173:676–682.
   PubMed Web of Science ®Google Scholar
• Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology. 2002;35:519–524.
   PubMed Web of Science ®Google Scholar
• Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015;33:550–558.
   PubMed Web of Science ®Google Scholar
• Malinchoc M, Kamath PS, Gordon FD, et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology. 2000;31:864–871.
   PubMed Web of Science ®Google Scholar
• Ahmed M, Solbiati L, Brace CL, et al.; Standard of Practice Committee of the Cardiovascular and Interventional Radiological Society of Europe. Image-guided tumor ablation: standardization of terminology and reporting criteria – a 10-year update. Radiology. 2014;273:241–260.
   PubMed Web of Science ®Google Scholar
• Popper H. Aging and the liver. Prog Liver Dis. 1986;8:659–683.
   PubMedGoogle Scholar
• Zoli M, Iervese T, Abbati S, et al. Portal blood velocity and flow in aging man. Gerontology. 1989;35:61–65.
   PubMed Web of Science ®Google Scholar
• Olshansky SJ, Carnes BA, Désesquelles A. Demography. Prospects for human longevity. Science. 2001;291:1491–1492.
   PubMed Web of Science ®Google Scholar
• Vaupel JW, Carey JR, Christensen K, et al. Biodemographic trajectories of longevity. Science. 1998;280:855–860.
   PubMed Web of Science ®Google Scholar
• Ihle A, Jopp DS, Oris M, et al. Investigating discontinuity of age relations in cognitive functioning, general health status, activity participation, and life satisfaction between young-old and old-old age. Int J Environ Res Public Health. 2016;13:1092.
   Web of Science ®Google Scholar
• Baltes MM. The psychology of the oldest-old: the fourth age. Curr Opin Psychiatry. 1998;11:411–415.
   Web of Science ®Google Scholar
• Oishi K, Itamoto T, Kobayashi T, et al. Hepatectomy for hepatocellular carcinoma in elderly patients aged 75 years or more. J Gastrointest Surg. 2009;13:695–701.
   PubMed Web of Science ®Google Scholar
• Kaibori M, et al. Treatment optimization for hepatocellular carcinoma in elderly patients in a Japanese nationwide cohort. Ann Surg. 2019;270:121–130.
   PubMed Web of Science ®Google Scholar
• Famularo S, Di Sandro S, Giani A, et al. The impact of age and ageing on hepatocarcinoma surgery: short- and long-term outcomes in a multicentre propensity-matched cohort. Liver Int. 2019;39:894–904.
   PubMed Web of Science ®Google Scholar
• Cohen MJ. Trans-arterial chemo-embolization is safe and effective for very elderly patients with hepatocellular carcinoma. World J Gastroenterol. 2013;19:2521.
   PubMed Web of Science ®Google Scholar
• Nishikawa H, Kimura T, Kita R, et al. Treatment for hepatocellular carcinoma in elderly patients: a literature review. J Cancer. 2013;4:635–643.
   PubMed Web of Science ®Google Scholar
• Shen X, Ma S, Tang X, et al. Clinical outcome in elderly Chinese patients with primary hepatocellular carcinoma treated with percutaneous microwave coagulation therapy (PMCT). Medicine. 2018;97:e11618.
   PubMed Web of Science ®Google Scholar
• Curto S, Taj-Eldin M, Fairchild D, et al. Microwave ablation at 915 MHz vs 2.45 GHz: a theoretical and experimental investigation. Med Phys. 2015;42:6152–6161.
   PubMed Web of Science ®Google Scholar
• Vogl TJ, Hagar A, Nour-Eldin N-EA, et al. High-frequency versus low-frequency microwave ablation in malignant liver tumours: evaluation of local tumour control and survival. Int J Hyperthermia. 2016;32:868–875.
   PubMed Web of Science ®Google Scholar
• Hung AK, Guy J. Hepatocellular carcinoma in the elderly: meta-analysis and systematic literature review. World J Gastroenterol. 2015;21:12197–12210.
   PubMed Web of Science ®Google Scholar
• Kulik L, El-Serag HB. Epidemiology and management of hepatocellular carcinoma. Gastroenterology. 2019;156:477–491.e1.
   PubMed Web of Science ®Google Scholar